Colony-stimulating factors in the prevention of solid tumors induced by chemotherapy in patients with febrile neutropenia.
Haematologic toxicity and its most frequent complication, febrile neutropenia represents the main limiting factor to the use of anti-cancer chemotherapy. The recent availability of recombinant human colony stimulating factors offers a new opportunity to improve the tolerance of these treatments. Most randomized trials in various solid tumors have demonstrated the ability of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor to significantly reduce the incidence of febrile neutropenia and related complications. Interestingly enough, these compounds are well tolerated and easy to administrate. However, since the increase in dose-intensity does not translate into any improved efficacy in terms of response rates or survival, the use of colony-stimulating factors has to be decided on the basis of cost-benefit considerations. Therefore, some scientific societies such as the American Association of Clinical Oncology in the US and the Anti-Cancer Centers Group in France have published recommendations for their use in routine oncology practice. We here discuss these guidelines on the basis of an overview of the literature.
Freyer
G
G
Medical Oncology Unit, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France.
Ligneau
B
B
Trillet-Lenoir
V
V
D000970:Antineoplastic Agents / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D005334:Fever; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control*
D000970:Antineoplastic Agents; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor